Immune-modulating-cancer

Electrical Stimulation for Immune Modulation in Cancer Treatments

A promising approach to reducing the dose of immunotherapeutic agents given to a cancer patient is to combine it with electrical stimulation, which can act in two ways; it can either modulate the ... read more

Immunotherapy against Solid Tumors May Be More Effective with Intact Lymph Nodes

Human study results suggest that leaving lymph nodes in place until after immunotherapy could boost efficacy against solid tumors. read more

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology ... read more

Community philanthropists donate $1M to groundbreaking cancer research at LHSC

Andy and Helen Spriet, a local couple well known for their philanthropy efforts throughout the city, have made a donation of $1 million in support of Dr. Saman Maleki's pioneering immuno-oncology ... read more

Macomics clinches cancer drug deal with Ono Pharmaceutical

Macomics Ltd, a Cambridge-based leader in macrophage drug discovery, has entered into a worldwide drug discovery collaboration with Ono Pharmaceutical in Japan to develop new immuno-oncology antibody ... read more

iOnctura reveals roginolisib research results

Therapy prevents tumour proliferation while breaking immune tolerance among cancer patients iOnctura – a company concentrating on breakthrough cancer therapies – has announced the publication of ... read more

Grand Challenges in Modulating the Immune Response With RNAi Nanomedicines

The immune system is composed of many subsets of ... TARGETED DELIVERY OF PLK1-SIRNA BY SINGLE-CHAIN ANTIBODY SUPPRESSES HER2+ BREAST CANCER GROWTH AND METASTASIS (2011), MANUSPRIPT SUBMITTED]. read more

IO Biotech To Participate In March 2023 Investor Conferences

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine ... read more

iOnctura's roginolisob has potential for patients with solid and hematological tumors

Non-clinical research has been published about roginolisob, iOnctura’s non-ATP competitive alloseteric modulator of PI3Kδ, for the potential treatment of patients with solid and hematological tumors. read more

iOnctura announces publication of pioneering research describing the unique biological features of roginolisib

Onctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces the publication of non-clinical research on roginolisib in the ... read more